ArticleBMC gastroenterology2025
Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlthough systemic inflammatory response syndrome (SIRS) is associated with the progression of cirrhosis, its clinical significance in patients with cirrhosis and hepatic encephalopathy (HE) remains unclear.
methodsHere, clinical data of 161 hospitalized patients with cirrhosis and HE were analyzed.
resultsOf these patients, 60 (37.3%) developed SIRS and 40 (24.8%) died during hospitalization. Risk factors for death during hospitalization on univariate Cox analysis were as follows: a model for end-stage liver disease (MELD) score > 18; SIRS; serum C-reactive protein (CRP) > 10 mg/L; white blood cells (WBC), neutrophils (NEU), neutrophils/lymphocyte ratios (NLR), serum total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST); creatinine (Cr); international normalized ratio (INR). SIRS and a MELD score > 18, were significant independent risk factors (hazard ratio 4.758, 2.539; 95% confidence interval 2.115-10.703, 1.210-5.331; P < 0.001, P < 0.05, respectively). The 28-day survival rates were 95.8%, 89.6%, 61.1%, 37.5%, and 12.5% for SIRS scores of 0, 1, 2, 3, and 4, respectively (P < 0.001). Among patients with a MELD score ≤ 18, mortality was 7% in those without SIRS and 30% in those with SIRS. When a MELD score > 18, mortality was 16% in patients without SIRS and 62% in those with SIRS (P < 0.001). Among uninfected patients, mortality was 4% in those without SIRS and 43% in those with SIRS. Among infected patients the mortality rate was 19% in those who did not meet SIRS diagnostic criteria and 53% among those who met them (P < 0.001).
conclusionsThis study found that SIRS is a common independent risk factor for death among patients with liver cirrhosis hospitalized for HE. Early identification and treatment of SIRS is essential for improving survival in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.